

## RESEARCH ARTICLE

## Open Access



# Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab

Emilio Besada

## Abstract

**Background:** Randomized controlled trials and retrospective studies in ANCA-associated vasculitis (AAV) concurred that rituximab (RTX) is effective to induce and maintain remission. Infections and hypogammaglobulinemia during RTX were usually infrequent and uncomplicated. But in the Tromsø study cohort, 45 % of patients with granulomatosis with polyangiitis (GPA) developed hypogammaglobulinemia during RTX maintenance leading to its discontinuation in 62 %.

**Methods:** To explain these differences in outcome when using RTX in AAV to maintain remission, we used statistical structural methods to compare the Tromsø study cohort with other published cohorts.

**Results:** GPA patients' characteristics of the Tromsø study cohort were not so different compared with other cohorts. Rates of hypogammaglobulinemia and discontinuation of RTX seemed closely related to the cut-off used and to the levels of immunoglobulin (Ig) at baseline. Combination of low IgG serum levels at baseline (7.7 g/L) and low cut-off to define hypogammaglobulinemia in the Tromsø study cohort explained the high rate of hypogammaglobulinemia and discontinuation of RTX.

**Conclusions:** Patients' characteristics in the Tromsø study cohort were not skewed, apart from IgG levels. Low IgG level at baseline seemed to contribute the most to hypogammaglobulinemia and its complications.

**Keywords:** ANCA-associated vasculitis, Rituximab, Induction, Maintenance, Immunoglobulin, Hypogammaglobulinemia, Discontinuation, Adverse event, Principal component analysis, Correspondence analysis

## Background

Granulomatosis with polyangiitis (GPA) is an ANCA-associated vasculitis (AAV) affecting usually the small and medium vessels and is closely related to proteinase3-ANCA (PR3-ANCA). GPA often involves the upper and lower airways tracts and kidneys and was a fatal disease prior to the use of cyclophosphamide (CYC) [1].

Rituximab (RTX) is a chimeric monoclonal antibody against CD20 that depletes B cells [2] and is effective in inducing and maintaining remission in AAV patients in randomized controlled studies [3–5]. In two

retrospective studies of remission maintenance with RTX, severe infections and hypogammaglobulinemia were frequent adverse events: 26–29 % had severe infections and 41–45 % had hypogammaglobulinemia [6–8]. However interpretation of the risk of hypogammaglobulinemia and its practical implications differed between the two studies. In the Tromsø study cohort, 17 % received intravenous immunoglobulin (IVIG) replacement and 62 % who developed hypogammaglobulinemia discontinued maintenance remission with RTX [8].

To explain differences in outcome, we compared using statistical structural methods the patients' characteristics of the Tromsø study cohort with other published studies of induction and maintenance with RTX in AAV.

Correspondence: [emilio.besada@uit.no](mailto:emilio.besada@uit.no)

Bone and Joint Research Group, Institute of Clinical Medicine, UiT The Arctic University of Norway, 9037 Tromsø, Norway

## Methods

### Identification of induction and maintenance studies

Two studies from the Northern Norwegian vasculitis register that was approved in 2001 by the Regional Ethical Committee for Medical and Health Research Ethics (REK-V 41/2001) were included [6, 8]. Patients (or the patients' parents or guardians in case of children) gave written informed consent in accordance to the declaration of Helsinki at registry inclusion.

All other induction and maintenance studies with RTX in AAV were retrieved either from searching PubMed ([www.ncbi.nlm.nih.gov/pubmed](http://www.ncbi.nlm.nih.gov/pubmed)) in January 2015 using indexing terms ANCA vasculitis, rituximab maintenance and induction, or from reviewing the reference lists.

All studies of nine or more AAV patients were included in the analysis. Eighteen induction [3, 4, 6, 9–24] and 11 maintenance studies [5–8, 24–32] were identified. Definition of severe infections was similar in all studies, while definition of hypogammaglobulinemia differed.

### Statistical analysis

Principal component analysis (PCA) finds the best linear combinations of important variables at baseline. Number

of patients, age, proportion of men, PR3-ANCA status, kidney and lung involvement, Birmingham vasculitis score (BVAS) at baseline, proportion of patients exposed to CYC and type of RTX induction regimen were included in the PCA of induction studies. Number of patients, age, PR3-ANCA status, kidney and lung involvement, exposure to CYC, disease duration prior RTX and follow-up in months were included in the PCA of maintenance studies. Correspondence analysis (CA) of adverse events during RTX maintenance included studies that reported the risks of both severe infections and hypogammaglobulinemia.

Statistical analysis was done with R (R project for statistical computing [www.r-project.org](http://www.r-project.org)).

## Results

### Induction

Ten studies out of 18 were included in the PCA. Missing data from studies not included in the PCA were PR3-ANCA status [20, 21, 23], lung involvement [3, 22], CYC exposure [13, 17] and BVAS [12, 20] (Table 1 and Fig. 1). All studies concluded that RTX was effective in inducing remission in AAV patients, even though patients' characteristics and induction regimen were different. The two first PCA dimensions explained 59 % of the variance of the cohorts' characteristics included in the analysis.

**Table 1** Characteristics of ANCA-associated vasculitis patients who received rituximab for remission induction

Study place	N	Men	Age	PR3-ANCA	Kidney	Lung	Orbital Subglottic	CYC exposed	Time to RTX	FU	RTX 1gx2	BVAS	IgG prior	IgG after	HypoG	SI	Ref
		%	y	%	%	%	%	%	mo	mo	%		g/L	g/L	%	%	
Linköping, Sweden	9	56	59	78	78	44	NA	100	36	12	0	6	8.4	6.4	NR	0	10
Rochester, US	10	70	57	100	70	40	10	100	59	9	0	6	NR	NR	NR	20	11
MC, UK	65	52	47	57	10	40	20	97	72	20	49	NR	7.9	8.0	0	20	12
Boston, US	39	49	60	62	NR	NR	NR	NR	67	18	90	1	NR	NR	0	3	13
Bad-Bramstedt Germany	59	59	54	86	44	41	46	100	37	7	0	11	8.6	6.9	12	26	14
Freiburg, Germany	37	57	62	81	60	81	NR	92	99	30	81	13	9.9	9.0	27	16	24
Goteborg, Sweden	29	52	51	97	62	59	38	100	31	21	0	6	NR	NR	NR	10	15
Stockholm, Sweden	16	56	60	81	50	50	NR	100	68	20	38	10	NR	NR	NR	38	16
London UK 2014	19	26	61	53	53	32	NR	NR	40	11.5	0	7	NR	NR	0	0	17
Munich, Germany	17	59	58	76	71	59	53	76	40	24	0	13	NR	NR	NR	24	18
Cleveland, US	105	48	49	75	58	83	NA	88	55	23	73	4	NR	NR	NR	7	19
London, UK 2009	10	50	49	NR	40	0	70	90	78	12	100	NR	NR	NR	NR	0	20
Torino, Italy	11	55	58	NR	64	27	NR	82	22	NR	0	23	8.0	6.7	NR	NR	21
London, UK 2011	23	52	59	70	100	NR	NR	100	1	36	100	21	NR	NR	4	9	22
Registry Germany	58	48	50	NR	45	59	19	60	54	18	47	13	NR	NR	NR	7	23
RAVE US	99	46	54	67	66	52	NR	42	30	6	0	9	NR	NR	NR	7	4
RITUXIVAS EUVAS	33	52	68	53	100	NR	NR	100	1	12	0	19	NR	NR	3	19	3
Tromsø, Norway	29	52	50	86	59	66	62	97	57	49	100	10	7.7	NR	NR	NR	8

*BVAS* Birmingham Vasculitis Activity Score, *CYC* cyclophosphamide, *FU* follow-up during maintenance remission with rituximab, *HypoG* rate of hypogammaglobulinemia, *MC* multicentric study, *N* number of patients, *NR* not reported, *RTX* rituximab, *Ref* reference, *SI* rate of severe infection

The RAVE and Cleveland Clinic studies recruited the most patients [4, 19]. The two 1g- RTX infusions given one fortnight apart were used more often at induction in the studies from Freiburg and Tromsø [8, 24].

Patients in the Tromsø cohort only had GPA, were more often PR3-ANCA positive, had more lung and less kidney involvement, received more frequently CYC and had a higher BVAS at baseline (Fig. 1).

### Maintenance


The PCA did not include two studies that reported neither age [31] nor exposure to CYC [29]. Studies were very different in term of patients' characteristics at baseline, however all reported decreased disease activity and relapse rates during RTX maintenance (Table 2 and Fig. 2). The two first PCA dimensions explained 64 % of the variance of the cohorts' characteristics included in the analysis.

Studies from Freiburg [24] and two other multicentric French studies [5, 32] were closely related, as their patients were older at RTX induction, had more kidney and lung involvement and had the shortest follow-up after RTX. Almost all patients were PR3-ANCA positive in the studies from Mayo Clinic and Nottingham [25, 28]. Cohorts from Tromsø and Paris were closest to the centroid (point 0) [8, 26].

Patients in the Tromsø cohort only had GPA, were younger, more often PR3-ANCA positive and received more frequently CYC prior to RTX (Fig. 2).

### Severe infection and hypogammaglobulinemia during maintenance

A total of 18 % (range 11–33 %) of patients had severe infections during RTX maintenance [5–7, 24, 29–32]; 18 % (2 – 45 %) developed hypogammaglobulinemia [7, 8, 24, 25, 29, 30]. The CA included five cohorts [6–8, 24, 29, 30]




**Fig. 1** Principal component analysis of rituximab induction studies. 1: DE-Bad-Bramstedt [14]; 2: US-Cleveland [19]; 3: DE-Freiburg [24]; 4: DE-Munich [18]; 5: SE-Gothenburg [15]; 6: SE-Stockholm [16]; 7: RAVE study [4]; 8: US-Rochester [11]; 9: SE-Linköping [10]; 10: NO-Tromsø [6]. Age: age in years; BVAS: Birmingham Vasculitis Activity Score; CYC: proportion of patients exposed to cyclophosphamide; Kidney: proportion of patients with kidney involvement; Lung: proportion of patients with lung involvement; Men: proportion of men in studies; N: number of patients in studies; PR3: proportion of patients who are PR3-ANCA positive; RTX\_1gx2: proportion of patients who received rituximab 1g twice given one fortnight apart (rheumatoid arthritis protocol)


**Table 2** Characteristics of ANCA-associated vasculitis patients who received rituximab for remission maintenance

Study place	N	Age y	Men %	PR3- ANCA %	CYC %	CYC g	RTX g	Kidney %	Lung %	Orb- Subg %	BVAS	Time to RTX mo	FU mo	IgG before g/L	IgG after g/l	SI %	HypoG %	Ref
Nottingham, UK	11	41	64	100	100	NR	8	55	46	NR	14	72	32	NR	NR	NR	9	25
Paris 2011, France	28	51	60	68	100	48	NR	32	64	14	15	84	38	7.8	7.0	11	11	26
Rochester, US	53	46	47	98	100	NR	NR	42	49	NR	5	120	53	8.4	5.7	NR	NR	28
Freiburg, Germany	37	62	57	81	92	12	NR	60	81	NR	13	99	30	9.9	NR	16	27	24
Boston, US	172	60	45	43	NR	NR	NR	62	44	NR	2	NR	25	NR	NR	15	10	29
Paris 2014, France	66	50	49	80	89	29	4.6	21	47	14	10	67	34	8.3	7.5	14	2	30
Uppsala, Sweden	12	NR	42	100	100	61	NR	50	100	42	9	35	79	8.5	6.8	33	NR	31
MC, France	80	53	NR	84	98	13	NR	55	71	10	7	54	18	NR	NR	15	NR	32
Mainritsan, France	57	54	65	77	100	7.3	2.5	70	58	NR	NR	3	28	6.1	6.9	19	NR	5
Cambridge, UK	69	52	41	74	91	13.5	6	12	29	12	NR	60	59	9.3	8.0	29	41	7
Tromsø, Norway	29	50	52	86	97	17	9	59	66	62	10	57	49	7.7	4.9	24	45	8

BVAS Birmingham Vasculitis Activity Score, CYC cyclophosphamide, FU follow-up during maintenance remission with rituximab, HypoG rate of hypogammaglobulinemia, MC multicentric study, N number of patients, NR not reported, Orb-Subg frequency of orbital-subglottic involvement, RTX rituximab, Ref reference, SI rate of severe infection



**Fig. 2** Principal component analysis of rituximab maintenance studies. 1: DE-Freiburg [24]; 2: FR-MC [32]; 3: FR-MAINRITSAN study [5]; 4: NO-Tromsø [6, 8]; 5: UK-Cambridge [7]; 6: US-Rochester [28]; 7: FR-Paris 2012 [26]; 8: UK-Nottingham [25]; 9: FR-Paris 2014 [30]. Age in years; CYC: proportion of patients exposed to cyclophosphamide; Follow\_up: follow-up of remission maintenance with rituximab; Kidney: proportion of patients with kidney involvement; Lung: proportion of patients with lung involvement; N: number of patients included in the studies; PR3: proportion of patients with positive PR3-ANCA; Time\_RTX: disease duration prior to rituximab



as data of both severe infection and hypogammaglobulinemia were lacking in most studies. The Tromsø and Cambridge study cohorts had more severe infection and hypogammaglobulinemia [6–8] compared with Freiburg, Paris and Boston [24, 29, 30] (Fig. 3). Risks of severe infections and hypogammaglobulinemia were equivalent in the studies of Cambridge and Tromsø [6–8]. While severe hypogammaglobulinemia occurred in 7 % of the patients in the Cambridge cohort [7], hypogammaglobulinemia led to RTX discontinuation in 62 % and 53 % in the Tromsø and Boston cohorts [8, 29].

Ig levels were lower in patients from the Tromsø study cohort both at baseline and during RTX maintenance: IgG 7.7 compared with > 8.3 g/L at baseline in the other studies [7, 24, 29, 30] and IgG 4.9 during maintenance compared with > 7.0 in Boston [29], 7.5 in Paris [30], 8.0 in Cambridge [7] and 9.0 in Freiburg [24].

## Discussion

The Tromsø study cohort only included GPA patients; they were more frequently PR3-ANCA positive and were often exposed to CYC compared with other cohorts. Patients' characteristics of the Tromsø cohort were similar to Freiburg during induction [24] and to an older cohort from Paris during maintenance [26]. The Tromsø study cohort seemed representative of maintenance studies since it was close to the centroid of the PCA.

In AAV, the risks of hypogammaglobulinemia and of severe infection seemed equivalent at 18 % during remission maintenance with RTX. While severe infection was defined alike in all studies, the definition of hypogammaglobulinemia was not standardized and identified patients with different Ig serum levels conferring different risk to receive IVIG and to discontinue RTX. Hypogammaglobulinemia cutoff was lowest in the Boston study: total IgG < 4 g/L [29] vs. IgG < 6 in Cambridge [7], IgG < 7 [24] in Freiburg, total Ig < 6 (corresponding to IgG < 5 g/L) in Tromsø [8] and total Ig < 7 g/L in Paris [30]. Difference in cutoffs explained the difference in results between studies, but hypogammaglobulinemia in the Tromsø study was still more frequent and severe.

Fifty three and 62 % discontinued RTX maintenance due to hypogammaglobulinemia in the Boston and Tromsø cohorts [8, 29]. However the risk of hypogammaglobulinemia was four times higher in the Tromsø cohort since the Boston study used a lower cutoff to define hypogammaglobulinemia [29].

The Cambridge and Tromsø studies had an increased risk of hypogammaglobulinemia, respectively 41–45 % [6–8]. However the impact of hypogammaglobulinemia was more severe in the Tromsø study. In the Tromsø study, patients had lower IgG levels during RTX maintenance and 17 % required intravenous immunoglobulin

(IVIG) replacement [8]. Only 7 % required IVIG in the Cambridge study [7].

PR3-ANCA status and exposure to CYC prior to RTX were similar in the Tromsø and Cambridge cohorts. Nevertheless others factors, such as organ involvement and treatment strategy during remission maintenance, could also explain the differences in severity of hypogammaglobulinemia between both studies. GPA patients in the Tromsø study had more lung and kidney involvement than in Cambridge. They also used concomitant immunosuppressive drugs for a median of two years and continued with pre-emptive RTX maintenance for a median of four years. While in the Cambridge study, patients did not use concomitant immunosuppressive drugs, received RTX remission maintenance during two years and were only re-treated with RTX in case of relapse [7].

## Conclusions

In summary, GPA patients' characteristics in the Tromsø cohort were not skewed compared with the other cohorts, apart from IgG levels. In agreement with a previous study on RTX use in autoimmune diseases [33], low IgG level at baseline seemed to contribute the most to hypogammaglobulinemia and its complications during RTX maintenance in AAV.

## Ethics approval and consent to participate

Human data originated from the Northern Norwegian vasculitis register that was approved in 2001 by the Regional Ethical Committee for Medical and Health Research Ethics (REK-V 41/2001). Patients (or the patients' parents or guardians in case of children) gave written informed consent in accordance to the declaration of Helsinki at registry inclusion.

## Abbreviations

AAV: ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic antibodies; BVAS: Birmingham vasculitis activity score; CA: correspondence analysis; CYC: cyclophosphamide; GPA: granulomatosis with polyangiitis; Ig: immunoglobulin; IVIG: intravenous immunoglobulin; PCA: principal component analysis; PR3: proteinase 3; RTX: rituximab.

## Competing interests

The author declares that he has no competing interests.

## Author's contribution

EB acquired, analyzed and interpreted the data. EB was involved in drafting the manuscript and revising it critically. EB has given formal approval of the version to be published. EB agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The author read and approved the final manuscript.

Received: 9 June 2015 Accepted: 23 December 2015

Published online: 06 January 2016

## References

1. Fauci AS, Wolff SM. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. *Medicine*. 1973;52:535–61.

2. Leandro MJ, de la Torre I. Translational mini-review series on B cell directed therapies: the pathogenic role of B cells in autoantibody-associated autoimmune diseases – lessons from B cell-depletion therapy. *Clin Exp Immunol* 2009;doi:10.1111/j.1365-2249.2009.03977.x
3. Jones RB, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med*. 2010;363:211–20.
4. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med*. 2010;363:221–32.
5. Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. *N Engl J Med*. 2014;371:1771–80.
6. Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. *Rheumatology*. 2013;52:2041–7.
7. Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. *Rheumatology* 2014; doi:10.1093/rheumatology/keu452.
8. Besada E, Koldingsnes W, Nossent JC. Serum immunoglobulin levels and risk factors for hypogammaglobulinemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. *Rheumatology*. 2014;53:1818–24.
9. Venhoff N, Effelsberg NM, Salzer U, Warnatz K, Peter HH, Lebrecht D et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. *Plos ONE* 7(5):e37626. doi:10.1371/journal.pone.0037626.
10. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. *J Intern Med*. 2005;257:540–8.
11. Keogh KA, Ytterberg SR, Fervenza FC, Carlsson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. *Am J Respir Crit Care Med*. 2006;173:180–7.
12. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum*. 2009;60:2156–68.
13. Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance antibody for anti-neutrophil cytoplasmic antibody-associated vasculitis. *Clin J Am Soc Nephrol*. 2010;5:1394–400.
14. Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. *Ann Rheum Dis*. 2012;71:327–33.
15. Pullerits R, Ljevack M, Vikgren J, Bokarewa M. Off-trial evaluation of the B-cell targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre. *Scand J Immunol*. 2012;76:411–20.
16. Wendt M, Gunnarsson I, Bratt J, Bruchfeld A. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. *Scand J Rheumatol*. 2012;41:116–9.
17. Turner-Stokes T, Sandhu E, Pepper RJ, Stologiewicz NE, Ashley C, Dinneen D, et al. Induction treatment of ANCA-associated vasculitis with a single dose of rituximab. *Rheumatology*. 2014;53:1395–403.
18. Moog P, Probst M, Kuehle C, Hauser C, Heemann U, Thuermerl K. Single-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: a retrospective analysis of 17 patients. *Scand J Rheumatol*. 2014;43:519–23.
19. Azar L, Springer J, Langford CA, Hoffman GS. Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener's). *Arthritis Rheum*. 2014;66:2862–70.
20. Taylor S, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. *Arthritis Rheum*. 2009;60:1540–7.
21. Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Russo A, et al. Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis. *Am J Nephrol*. 2011;34:175–80.
22. Mansfield N, Hamour S, Habib AM, Tarzi R, Levy J, Griffith M, et al. Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. *Nephrol Dial Transplant*. 2011;26:3280–6.



23. Roll P, Ostermeier E, Haubitz M, Lovric S, Unger L, Holle J, et al. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). *J Rheumatol*. 2012;39:2153–6.
24. Venhoff N, Niessen L, Kreuzaler M, Rolink AG, Hässler F, Rizzi M, et al. Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease. *Autoimmunity*. 2014;47:401–8.
25. Rees F, Yazdani R, Lanyon P. Long-term follow-up of different refractory systemic vasculitides treated with rituximab. *Clin Rheumatol*. 2011;30:1241–5.
26. Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N, Grasland A, Zoulim A, Le Guen J, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. *J Rheumatol*. 2012;39:125–30.
27. Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum*. 2012;64:3760–9.
28. Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sanchez-Menendez M, Ytterberg SR, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's). *Arthritis Rheum*. 2012;64:3770–8.
29. Pendergraft III WF, Cortazar FB, Wenger J, Murphy AP, Rhee EP, Laliberte KA, et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. *Clin J Am Soc Nephrol*. 2014;9:736–44.
30. Calich AL, Puéchal X, Pugnet G, London J, Terrier B, Charles P et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. *J Autoimmun*. 2014;50:135–41.
31. Knight A, Hallenberg H, Baecklund E. Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis — a case series. *Clin Rheumatol*. 2014;33:841–8.
32. Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, et al. Rituximab for induction and maintenance of ANCA associated vasculitides: a multicenter retrospective study on 80 patients. *Rheumatology*. 2014;53:532–9.
33. Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. *J Autoimmun*. 2015;57:60–5.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

